Skip to main content
NASDAQ:KALV

KalVista Pharmaceuticals News Headlines

$24.81
-0.60 (-2.36 %)
(As of 05/12/2021 12:00 AM ET)
Add
Compare
Today's Range
$24.37
$25.64
50-Day Range
$23.12
$30.57
52-Week Range
$9.03
$45.00
Volume353,763 shs
Average Volume836,745 shs
Market Capitalization$603.08 million
P/E RatioN/A
Dividend YieldN/A
Beta2.13

Headlines

KalVista Pharmaceuticals (NASDAQ KALV) News Headlines Today

SourceHeadline
KalVista Pharmaceuticals to Present Clinical Data of KVD900 for the Oral Treatment of Hereditary Angioedema at the 12th C1-Inhibitor Deficiency & Angioedema WorkshopKalVista Pharmaceuticals to Present Clinical Data of KVD900 for the Oral Treatment of Hereditary Angioedema at the 12th C1-Inhibitor Deficiency & Angioedema Workshop
finance.yahoo.com - May 10 at 8:52 AM
KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) Insider Christopher Yea Sells 5,000 SharesKalVista Pharmaceuticals, Inc. (NASDAQ:KALV) Insider Christopher Yea Sells 5,000 Shares
americanbankingnews.com - May 6 at 8:56 PM
KalVista Pharmaceuticals Sees Unusually Large Options Volume (NASDAQ:KALV)KalVista Pharmaceuticals Sees Unusually Large Options Volume (NASDAQ:KALV)
americanbankingnews.com - May 5 at 7:40 AM
KalVista Pharmaceuticals Expands Senior Leadership Team with Appointment of Paul K. Audhya, MD, MBA as Chief Medical OfficerKalVista Pharmaceuticals Expands Senior Leadership Team with Appointment of Paul K. Audhya, MD, MBA as Chief Medical Officer
finance.yahoo.com - May 3 at 11:08 AM
Insider Selling: KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) VP Sells 10,014 Shares of StockInsider Selling: KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) VP Sells 10,014 Shares of Stock
americanbankingnews.com - May 3 at 4:52 AM
KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) SVP Sells $284,128.43 in StockKalVista Pharmaceuticals, Inc. (NASDAQ:KALV) SVP Sells $284,128.43 in Stock
americanbankingnews.com - April 30 at 4:50 PM
Insider Selling: KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) SVP Sells 88,030 Shares of StockInsider Selling: KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) SVP Sells 88,030 Shares of Stock
americanbankingnews.com - April 30 at 1:22 PM
KalVista Pharmaceuticals (NASDAQ:KALV) Shares Gap Up to $24.47KalVista Pharmaceuticals (NASDAQ:KALV) Shares Gap Up to $24.47
americanbankingnews.com - April 27 at 11:18 AM
KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) Given Average Rating of "Buy" by AnalystsKalVista Pharmaceuticals, Inc. (NASDAQ:KALV) Given Average Rating of "Buy" by Analysts
americanbankingnews.com - April 25 at 6:24 AM
KalVista Pharmaceuticals (NASDAQ:KALV) Trading Down 4.3%KalVista Pharmaceuticals (NASDAQ:KALV) Trading Down 4.3%
americanbankingnews.com - April 23 at 3:42 PM
What You Need To Know About KalVista Pharmaceuticals, Inc.s (NASDAQ:KALV) Investor CompositionWhat You Need To Know About KalVista Pharmaceuticals, Inc.'s (NASDAQ:KALV) Investor Composition
nasdaq.com - April 22 at 7:25 PM
KalVista Pharmaceuticals (NASDAQ:KALV) Trading 7.7% Higher KalVista Pharmaceuticals (NASDAQ:KALV) Trading 7.7% Higher
americanbankingnews.com - April 22 at 1:58 PM
KalVista Stock Falls After FDA Institutes Clinical Hold On Hereditary Angioedema Trial With KVD824KalVista Stock Falls After FDA Institutes Clinical Hold On Hereditary Angioedema Trial With KVD824
finance.yahoo.com - April 20 at 12:21 PM
KalVista Pharmaceuticals (NASDAQ:KALV) Shares Gap Down to $23.12KalVista Pharmaceuticals (NASDAQ:KALV) Shares Gap Down to $23.12
americanbankingnews.com - April 20 at 11:40 AM
KalVista Pharmaceuticals Provides Regulatory Update for Phase 2 Clinical Trial of KVD824KalVista Pharmaceuticals Provides Regulatory Update for Phase 2 Clinical Trial of KVD824
finance.yahoo.com - April 20 at 7:21 AM
KalVista Pharmaceuticals IncKalVista Pharmaceuticals Inc
bloomberg.com - April 18 at 10:30 PM
What Is The Ownership Structure Like For KalVista Pharmaceuticals, Inc. (NASDAQ:KALV)?What Is The Ownership Structure Like For KalVista Pharmaceuticals, Inc. (NASDAQ:KALV)?
finance.yahoo.com - March 29 at 9:05 AM
KalVista Pharmaceuticals, Inc. (KALV) Moves to Buy: Rationale Behind the UpgradeKalVista Pharmaceuticals, Inc. (KALV) Moves to Buy: Rationale Behind the Upgrade
finance.yahoo.com - March 17 at 2:54 PM
KalVista Pharmaceuticals Reports Third Fiscal Quarter ResultsKalVista Pharmaceuticals Reports Third Fiscal Quarter Results
finance.yahoo.com - March 11 at 8:40 AM
KalVista Pharmaceuticals, Inc. (KALV) Reports Q3 Loss, Misses Revenue EstimatesKalVista Pharmaceuticals, Inc. (KALV) Reports Q3 Loss, Misses Revenue Estimates
finance.yahoo.com - March 11 at 8:40 AM
KalVista Pharmaceuticals, Inc. (KALV) Expected to Beat Earnings Estimates: Should You Buy?KalVista Pharmaceuticals, Inc. (KALV) Expected to Beat Earnings Estimates: Should You Buy?
finance.yahoo.com - March 2 at 5:24 PM
KalVista Pharmaceuticals Announces the Closing of its Upsized Public Offering of Common Stock and Full Exercise of the Underwriters’ Option to Purchase Additional SharesKalVista Pharmaceuticals Announces the Closing of its Upsized Public Offering of Common Stock and Full Exercise of the Underwriters’ Option to Purchase Additional Shares
finance.yahoo.com - February 16 at 5:41 PM
KalVista Pharmaceuticals Raises $193.5M Via Equity To Fund KVD900 DevelopmentKalVista Pharmaceuticals Raises $193.5M Via Equity To Fund KVD900 Development
markets.businessinsider.com - February 11 at 9:58 AM
KalVista Pharmaceuticals Announces Pricing of an Upsized $193.5 Million Public Offering of Common StockKalVista Pharmaceuticals Announces Pricing of an Upsized $193.5 Million Public Offering of Common Stock
finance.yahoo.com - February 10 at 10:27 PM
Why KalVista Pharmaceuticals Stock Skyrocketed 115% TodayWhy KalVista Pharmaceuticals Stock Skyrocketed 115% Today
finance.yahoo.com - February 10 at 1:31 AM
KalVista Pharmaceuticals Announces Proposed Public Offering of Common StockKalVista Pharmaceuticals Announces Proposed Public Offering of Common Stock
finance.yahoo.com - February 9 at 8:30 PM
KalVista Touches 5-Year High On Overwhelmingly Positive Test ResultsKalVista Touches 5-Year High On 'Overwhelmingly Positive' Test Results
finance.yahoo.com - February 9 at 8:30 PM
KalVista Reports Positive Test Results for Angioedema Drug; Shares SoarKalVista Reports Positive Test Results for Angioedema Drug; Shares Soar
msn.com - February 9 at 3:30 PM
KalVista Surges 140% On Positive HAE ReadoutKalVista Surges 140% On Positive HAE Readout
msn.com - February 9 at 3:30 PM
Stock Alert: KalVista Pharmaceuticals More Than DoublesStock Alert: KalVista Pharmaceuticals More Than Doubles
nasdaq.com - February 9 at 3:30 PM
Heres Why KalVista Pharma Is Soaring Today?Here's Why KalVista Pharma Is Soaring Today?
nasdaq.com - February 9 at 3:30 PM
Investors Cheer Positive Data From KalVistas KVD900 Mid-Stage Hereditary Angioedema TrialInvestors Cheer Positive Data From KalVista's KVD900 Mid-Stage Hereditary Angioedema Trial
finance.yahoo.com - February 9 at 3:30 PM
KalVista Rockets To 5-Year High On Overwhelmingly Positive Test ResultsKalVista Rockets To 5-Year High On 'Overwhelmingly Positive' Test Results
finance.yahoo.com - February 9 at 3:30 PM
The Daily Biotech Pulse: Dynavax Poaches GSK Vaccine Exec, KalVista Jumps On Data Readout, Corcept Issues Negative PreannouncementThe Daily Biotech Pulse: Dynavax Poaches GSK Vaccine Exec, KalVista Jumps On Data Readout, Corcept Issues Negative Preannouncement
markets.businessinsider.com - February 9 at 8:48 AM
KalVista Pharmaceuticals Reports Positive Results for KVD900 Phase 2 Demonstrating Statistically and Clinically Significant Responses Across All Endpoints as an Oral On-Demand ...KalVista Pharmaceuticals Reports Positive Results for KVD900 Phase 2 Demonstrating Statistically and Clinically Significant Responses Across All Endpoints as an Oral On-Demand ...
businesswire.com - February 9 at 8:48 AM
KalVista Pharmaceuticals Reports Positive Results for KVD900 Phase 2 Demonstrating Statistically and Clinically Significant Responses Across All Endpoints as an Oral On-Demand Treatment for HAE AttacksKalVista Pharmaceuticals Reports Positive Results for KVD900 Phase 2 Demonstrating Statistically and Clinically Significant Responses Across All Endpoints as an Oral On-Demand Treatment for HAE Attacks
finance.yahoo.com - February 9 at 8:47 AM
Calculating The Fair Value Of KalVista Pharmaceuticals, Inc. (NASDAQ:KALV)Calculating The Fair Value Of KalVista Pharmaceuticals, Inc. (NASDAQ:KALV)
finance.yahoo.com - January 27 at 9:05 AM
Are Options Traders Betting on a Big Move in KalVista Pharmaceuticals (KALV) Stock?Are Options Traders Betting on a Big Move in KalVista Pharmaceuticals (KALV) Stock?
finance.yahoo.com - January 11 at 6:45 PM
Is KALV A Good Stock To Buy Now?Is KALV A Good Stock To Buy Now?
finance.yahoo.com - December 16 at 10:58 PM
KalVista Pharmaceuticals Reports Second Fiscal Quarter ResultsKalVista Pharmaceuticals Reports Second Fiscal Quarter Results
finance.yahoo.com - December 10 at 9:34 AM
Unusual Options Activity Insight: KalVista PharmaceuticalsUnusual Options Activity Insight: KalVista Pharmaceuticals
finance.yahoo.com - November 16 at 3:50 PM
Is KalVista Pharmaceuticals (NASDAQ:KALV) In A Good Position To Invest In Growth?Is KalVista Pharmaceuticals (NASDAQ:KALV) In A Good Position To Invest In Growth?
finance.yahoo.com - November 15 at 12:29 PM
KalVista Pharmaceuticals to Present at Upcoming Investor ConferencesKalVista Pharmaceuticals to Present at Upcoming Investor Conferences
finance.yahoo.com - November 9 at 7:46 AM
Wednesday 11/4 Insider Buying Report: KALV, CRLWednesday 11/4 Insider Buying Report: KALV, CRL
marketwatch.com - November 6 at 3:21 PM
KalVista provides pipeline update on hereditary angioedema franchiseKalVista provides pipeline update on hereditary angioedema franchise
seekingalpha.com - October 15 at 12:14 PM
KalVista Pharmaceuticals, Inc. (4XC1.F)KalVista Pharmaceuticals, Inc. (4XC1.F)
in.finance.yahoo.com - October 14 at 3:31 PM
KalVista Pharmaceuticals Reports First Fiscal Quarter ResultsKalVista Pharmaceuticals Reports First Fiscal Quarter Results
finance.yahoo.com - September 14 at 11:53 AM
KalVista Pharmaceuticals to Present at Cantor Global Healthcare ConferenceKalVista Pharmaceuticals to Present at Cantor Global Healthcare Conference
finance.yahoo.com - September 11 at 10:39 AM
Introducing KalVista Pharmaceuticals (NASDAQ:KALV), A Stock That Climbed 93% In The Last Three YearsIntroducing KalVista Pharmaceuticals (NASDAQ:KALV), A Stock That Climbed 93% In The Last Three Years
finance.yahoo.com - August 27 at 12:58 PM
KalVista Pharmaceuticals (KALV) Q1 Earnings Preview: What to Look Out ForKalVista Pharmaceuticals (KALV) Q1 Earnings Preview: What to Look Out For
finance.yahoo.com - August 19 at 2:16 PM
This page was last updated on 5/13/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.